Pharmaceutical CAS 1092939 17 7 Ruxolitinib Phosphate

Share on (60792793069):


Price:RUB 4,691.21 - RUB 6,254.95

Quantity:


Product Overview

Description

2_01.jpg2_03.jpg

Identification

 

NameRuxolitinib Phosphate, CAS 1092939-17-7
Structure  
Other nameRuxolitinib phosphate
1092939-17-7
Ruxolitinib (phosphate)
(R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate
UNII-436LRU32H5
Ruxolitinib phosphate salt
Ruxolitinib phosphate(INCB018424)
Key wordsPharmaceutical, drug,Antineoplastic Agents; a Janus kinase inhibitor;  treatment of intermediate or high risk myelofibrosis
CAS NO.1092939-17-7
Molecular FormulaC17H21N6O4P
Molecular Weight404.367 g/mol

  

Chemical and Physical Properties
AppearanceWhite to off-white or light pink powder
SolubilityHighly soluble in water, and the solubility is pH dependant.
Quality standard Purity 98.0%~102.0%

 

Application
Drug IndicationRuxolitinib is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea.
Formulations/Preparationstablet
Handling and storage
Safety and HazardsThe shanghai Research Institute of Chemical industry testing center identification conclusion :1 None hazard identification, 2 The substance is not subject to IATA DGR, 3 Non packing requirements.
Handling and storageKeep container tightly closed in a dry and well-ventilated place. Light sensitive.
Sample packageAluminium foil bag
Commercial packageFiber drum
UN Code Not classfied
HS Code29419090.00
Shipping groupShipment at ambient temperature for no controlled and  no dangerous goods
Sales restrictionNO
OriginChina

 

Technical Support
Ruxolitinib Phosphate STD Data sheetYes
Ruxolitinib Phosphate MSDSYes
Ruxolitinib Phosphate COAYes
Ruxolitinib Phosphate Transport certificateYes

 

Supply ability
Monthly capacity10kg
GMPNone

 

Related APIs

Related APIS

Tofacitinib
Hydroxyurea
Imatinib
Nilotinib
Ibrotinib

 

 

 

2_06.jpg2_07.jpg2_08.jpg2_09.jpg

 
0.2068 s.